COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04347915

Woo-Joo Kim

Not reported

2020-04-15

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

key inclusion criteria: over 19 years of age covid-19 confirmed by a real-time rt-pcr tests 4 days prior to clinical trial enrollment patients with peripheral capillary oxygen saturation (spo2) greater than 94% at the time of screening patients whose body temperature is measured according to the measured area without taking a fever reducer during screening: [armpit of greater than 37.0 °c or an oral of greater than 37.2 °c; patients with rectum greater than 37.6 °c or eardrum greater than 37.5 °c] (notes: although you take a fever reducer, you can still be enrolled in after investigator's judgement whether there is fever or not.) patients with evidence of lung invasions as a result of radiation tests

patients who need breathing device (for example, invasive ventilation, invasive mechanical ventilation, extra-corporeal membrane oxygenation). patients who participated in other clinical trials related to covid-19. patients who were administered drugs directly to covid-19 24 hours prior to the start of the study. patients whose ast or alt has increased by more than 5 times the normal lab value.

2

Bukwang Pharmaceutical

19

None

Korea;Republic of

Moderate disease at enrollment

3: Moderate disease at enrollment

64

The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)

None

Phase 2

[{"arm_notes": "", "treatment_id": 295, "treatment_name": "Clevudine", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]